bioRxivPharmacology & ToxicologyPreprint
G protein subtype preference dictates paroxetine-enhanced serotonin receptor response in normal breast epithelial cells
Abstract
In the healthy mammary gland serotonin (5-HT) has a key role in shaping tissue morphology and regulating lactation and involution. Serotonin re-uptake inhibitors (SSRIs) alter the distribution of 5-HT across the cell membrane, but how increased extracellular 5-HT may impact breast cell homeostasis is unclear. We demonstrate that paroxetine reduces 5-HT levels in immortalized primary breast epithelial (HME-hTert) cells, mitigates free oxygen radical formation and decreases cell migration and proliferation. Accordingly, pathways related to cell cycle and DNA damage repair were underrepresented in the transciptomic profile of paroxetine-treated cells. On the other hand, enriched transcipts overrepresented genes affecting neural transmission and GPCR signaling, suggesting an increase in 5-HT receptor (5HTR) activation. As 5-HT induced the levels of both cAMP and inositol triphosphate (IP3), the contribution of individual 5HTRs were decyphered using receptor-selective agonists and antagonists. 5HTRs coupled to each G protein subtype were expressed and functional in HME-hTert cells. The activation of GS-coupled receptor 5HTR7 and antagonists of Gi- and Gq-coupled receptors 5HTR1D and 5HTR2B generally suppressed proliferation. The induction of cAMP levels by 5-HT was reduced by the 5HTR7 antagonist and IP3 induction was blocked by an 5HTR2B inhibitor, while the 5HTR1D antagonist further increased cAMP levels induced by 5-HT. Paroxetine-dependent growth suppression was reversed by inhibitors of GS-coupled 5HTR7, protein kinase A or adenylyl cyclase, and agonists of Gi or Gq-coupled receptors. These results suggest that the anti-proliferative responses to 5-HT in non-malignant breast cells align with the G protein preference of the receptors, and reveal potential benefits of repurposing receptor subtype-selective agents and SSRIs for cancer risk reduction. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=151 SRC="FIGDIR/small/658790v1_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@1a4e2a4org.highwire.dtl.DTLVardef@1b9ea7org.highwire.dtl.DTLVardef@14cfe9dorg.highwire.dtl.DTLVardef@1e02960_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Serotonin stimulated parathyroid hormone related protein induction in the mammary epithelia bytransglutaminase-dependent serotonylation
Celeste M. Sheftel, Laura L. Hernandez·PLoS ONEPeer-reviewed·Oct 23, 2020
- Antidepressant Sertraline Hydrochloride Inhibits the Growth of HER2+ AU565 Breast Cancer Cell Line through Induction of Apoptosis, and Arrest of Cell Cycle
A.-t.- Wahab, S. Fayyaz, … M. I. Choudhary·bioRxiv·Sep 7, 2021
- PTHrP Induces STAT5 Activation, Secretory Differentiation and Mammary Tumor Progression
D. Y. Grinman, K. Boras-Granic, … J. J. Wysolmerski·bioRxiv·Dec 28, 2021
- Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy
- Oxytocin receptor and HER2 interactions in breast cancer
Huiping Liu, Liying Liu, … Markus Muttenthaler·bioRxiv·Mar 9, 2025
- Serotonergic neuron-glioma interactions drive high-grade glioma pathophysiology
Richard Drexler, Belgin Yalçın, … Michelle Monje·bioRxiv·Dec 12, 2025